Revenue segments as reported by the company.

Cannabis revenue

Distribution revenue

Beverage alcohol revenue

Wellness revenue

Adult-use

Canada - Medical

International - Medical

Bulk

Hemp

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Impairment of Assets

Litigation settlement

Transaction costs

Change in fair value of contingent consideration

Restructuring costs

Other than temporary change in fair value of convertible notes receivable

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Tilray Brands

Tilray Brands, Inc. is a global cannabis-lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America. The firm is focused on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. Its products include dried cannabis and cannabis extracts. It operates through the following segments: Cannabis and Hemp. The Cannabis segment consists of adult-use, medical and bulk sales of cannabis under regulated licenses and sold to retail, wholesale, pharmacy, government, and direct to patient. The Hemp segment consists of hemp seed, hemp foods, and broad spectrum hemp extract containing CBD, which are sold in an unlicensed operation and sold to retail, wholesale and direct to consumers. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Earnings data Q1 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Tilray Brands reports record revenue and optimistic outlook for 2025

Tilray Brands achieved remarkable financial performance in Q4 2024, driven by strategic acquisitions and a focus on innovation. Despite challenges like price compression, the company remains optimistic about future growth opportunities. Tilray's commitment to quality products and innovation positions it well for continued success in the market.

Tilray Brands reports record Q1 revenue growth and global expansion

Tilray Brands delivered a robust performance in Q1 2025, showcasing strong revenue growth, margin improvement, and strategic expansion across its diversified product portfolio.
While facing challenges in a competitive landscape and evolving regulatory environment, Tilray's financial strength, international growth initiatives, and focus on innovation position it well for future success.
By capitalizing on opportunities in wellness products, expanding into new beverage categories, and leveraging strategic partnerships, Tilray is poised for continued growth and market leadership.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Tilray Brands, Inc. is a global cannabis-lifestyle and consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis Business, Distribution Business, Beverage Alcohol Business, and Wellness Business. The Cannabis Business segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution Business segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage Alcohol Business segment refers to the production, marketing, and sale of beverages. The Wellness Business segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Aphria

These stocks have chosen to weather the ups and downs of the marijuana industry with different growth strategies. But which has worked best?

Better Buy: Aphria vs. Tilray

Aurora Cannabis

AMC Entertainment

Peabody Energy

Cinemark Holdings

Macy's

Revlon

Spirit AeroSystems Hlds

Molson Coors Brewing

Wells Fargo

It’s been a wild ride in 2020. The greatest bull market ever turned into the fastest bear market ever, and the worst recession since the Great Depression was seen as the coronavirus turned into the COVID-19 pandemic.

9 Well-Known Stocks That Just Can’t Catch a Break

Block

Regeneron Pharmaceuticals

Square, Regeneron, Aphria and Tilray were our top stock trades for Tuesday. That said, here's how the charts look after Monday's action.

4 Top Stock Trades for Tuesday: SQ, REGN, APHA, TLRY

Investors pushed shares lower during the wider market's swoon.

Why Tilray Stock Dropped 28% in September

Cronos Group

GrowGeneration Corp

GW Pharmaceuticals

Village Farms International

These are the marijuana stocks on the NASDAQ with the best value, fastest growth, and best performance for October.

Top Marijuana Stocks on the NASDAQ for October 2020

The company is supplying the product for a series of studies being conducted in Australia.

Tilray Reports Positive Results for Medical Marijuana in Chemotherapy Patients

NANAIMO, B.C.--(BUSINESS WIRE)---- $TLRY #TLRY--Tilray announced preliminary results from a world-first clinical trial finding for chemotherapy induced nausea and vomiting.

Tilray Medical Cannabis Product Shows Promise Reducing Nausea and Vomiting Caused by Chemotherapy in World First Clinical Trial

These 2 Robinhood Stocks Are Down Around 15% This Month: Should You Buy the Dip?

Canopy Growth

Yes, but expect legalization efforts for recreational use to proceed unevenly from state to state.

Is the U.S. Getting on Board With Marijuana Legalization?

Cannabis stocks Tilray Inc. (NASDAQ: TLRY) and Aurora Cannabis Inc. (NYSE: ACB) traded lower on Monday amid a broad market sell-off.

Jefferies Upgrades Aurora And Tilray, Says Valuations, Estimates 'Now More Realistic'

If you only listened to CEO Brendan Kennedy's comments, you might feel bullish about Tilray stock, but the data paints a bleaker picture.
The post It’s Time to Admit Tilray Stock Isn’t Coming Back and Move On appeared first on InvestorPlace.

It’s Time to Admit Tilray Stock Isn’t Coming Back and Move On

Tilray’s been on a wild ride in 2020. At one point, Tilray stock was trading over $20.

Trading Under $10, Tilray Stock Could Still Tick Back Up To $20

Amplify Seymour Cannabis ETF

Curaleaf Holdings, Inc.

Green Thumb Industries Inc.

Amplify Alternative Harvest ETF

Global X Cannabis ETF

Constellation Brands

Trulieve Cannabis Corp.

AXS Cannabis ETF

Cambria Cannabis ETF

AdvisorShares Pure Cannabis ETF 

Master Class In Cannabis Investing, Part 1 (Podcast Transcript)

TLRY stock has faded of late — and may continue to do so. There simply isn't a compelling reason to own the stock in a sector with better opportunities.

Cannabis Bulls Can Do Better Than Tilray Stock

On paper, Tilray stock is supported by attributes that make it attractive during a pandemic. But the details tell a different story.

Investors Should Be Realistic with Tilray Stock

Here's why this battered cannabis stock may become the world leader in medical marijuana.

Is Tilray the Hottest Growth Stock to Buy Now?

HEXO Corp

These seven marijuana stocks to buy are solid long-term investments, because the industry still has a lot of growth left.

7 Marijuana Stocks to Buy As the Industry Continues to Grow

The company's coming off a disappointing quarter in which it reported a net loss of $81.7 million.

Is Tilray Stock In Trouble?

Both of these Canadian pot stocks are losers so far in 2020, but one seems better positioned to return to the winners' column.

Better Cannabis Stock: Cronos Group vs. Tilray

The company released its second-quarter financial results.

Why Tilray Stock Is Plunging Today

Although Tilray Inc. (NASDAQ: TLRY) reported its second-quarter sales below expectations, with disappointing recreational.

Cantor Cuts Tilray Target On Q2 Sales Miss

Tilray Inc. (NASDAQ: TLRY) reported its most recent quarterly results after the market closed on Monday, and investors were not happy.

What Analysts Are Saying About Tilray After Earnings

Tilray, Inc. (TLRY) CEO Brendan Kennedy on Q2 2020 Results - Earnings Call Transcript

On the bright side, total revenue rose, as did sales in the company's key product categories.

Tilray Stock Dives After Hours on Deepened Q2 Net Loss

Tilray, Inc. (TLRY) delivered earnings and revenue surprises of 3.70% and -8.87%, respectively, for the quarter ended June 2020.

Tilray, Inc. (TLRY) Reports Q2 Loss, Lags Revenue Estimates

News for Tilray Brands Stock (TLRY)